#USA #New York #First Databank #Hearst Health #David Delaney

David Delaney Appointed President of First Databank

In a significant leadership change, Hearst Health has announced the appointment of Dr. David Delaney as the new president of First Databank (FDB), a renowned provider of medication knowledge. With over two decades of experience in healthcare, Delaney is poised to drive innovation and enhance decision-making processes within the industry.

Hearst President and CEO Steven R. Swartz, alongside Hearst Health President Gregory Dorn, MD, made the announcement on February 24, 2026. Delaney's extensive background includes crucial roles in critical care and healthcare technology, which uniquely equip him for this leadership position at FDB. Most recently, he served as the senior vice president and general manager of clinical decision support at Optum Insight, where he was responsible for managing a wide range of evidence-based content and software solutions tailored for healthcare providers and payers.

Before his tenure at Optum, Delaney held executive roles at Change Healthcare and was the global vice president and chief medical officer for SAP Health. His extensive experience in clinical leadership and operational management will be invaluable as FDB continues to navigate the complexities of modern healthcare, especially in the realms of artificial intelligence (AI) and personalized medicine.

Dr. Dorn expressed the importance of Delaney’s appointment, stating that it represents Hearst Health's commitment to growth and innovation. Delaney’s leadership comes at a critical juncture for FDB, as the organization seeks to evolve its trusted medication knowledge system alongside the rapid advancements in AI-driven healthcare. The company aims to enhance the delivery of precise, patient-specific medication intelligence that healthcare organizations can reliably utilize in their clinical workflows.

Delaney’s journey in healthcare began with critical care medicine, where he led various applied informatics initiatives at Beth Israel Deaconess Medical Center. His firsthand experience with medication workflows and the complexities involved in prescribing has played a significant role in shaping his approach to healthcare technology. As a testament to his expertise, Delaney completed his medical training at premier Harvard-affiliated hospitals and holds several patents related to healthcare data management.

One of the key initiatives under Delaney’s leadership is the advancement of FDB’s platform strategy. He will focus on enhancing customer engagement, applying AI responsibly, and providing more accurate, patient-centered medication intelligence. As he takes on this new role, Delaney emphasized the importance of integrating technology that complements clinical rigor without compromising on quality or reliability. His goal is to foster deeper strategic collaborations across the healthcare ecosystem while reinforcing FDB's reputation as a trusted source for drug knowledge.

FDB has a long history of delivering clinically robust and actionable drug data, which is essential for improving patient safety and streamlining healthcare operations. By incorporating modern technology, Delaney aims to enhance the existing drug knowledge infrastructure to support clinicians in making informed medication decisions. This evolution is particularly crucial as healthcare organizations face increasing medication complexity and heightened expectations for personalized care.

Moreover, in recognition of the growing intersection between healthcare and technology, FDB has launched the industry’s first Model Context Protocol (MCP) server for clinical decision support. This innovative framework provides a standardized approach to integrating reliable medication knowledge directly into next-generation clinical applications driven by AI.

In conclusion, David Delaney’s appointment as president of First Databank marks a pivotal moment for the organization, as it continues to uphold its commitment to delivering high-quality medication intelligence. His leadership is expected to not only enhance FDB’s operational capabilities but also fortify its role as a leader in medication safety and innovation in a rapidly evolving healthcare landscape.